Gastric cancer is the fifth most common cancer worldwide, with about one million new cases reported in 2012 (6.8% of the total) \[[@b1-jptm-2017-11-01]\]. About 70% of cases occur in developed and developing countries a half of them are presented in East Asia (mainly in China) and twice as often in men over women. Although the incidence of gastric cancer has declined in recent decades, it remains the third leading cancer-related cause of death worldwide with 723,000, deaths representing 8.8% of all cancer deaths \[[@b1-jptm-2017-11-01]\]. The prognosis in advanced stages of gastric cancer is poor, even with the use of chemotherapy or other adjuvant treatments.

Perineural invasion (PNI) is one of the pathological factors widely studied in malignant neoplasms with a well-established prognostic significance in head and neck neoplasia and prostate cancer \[[@b2-jptm-2017-11-01]\]. PNI is related to a more aggressive behavior of the neoplasia and poor prognosis in several malignancies \[[@b3-jptm-2017-11-01]\]. However, there is no universal definition of PNI. Several pathologists simply define PNI as the presence of neoplastic cells in, around or through the nerves, while others require the presence of tumor cells within any of the epineurium, perineurium, or endoneurium. The most accepted one was defined by Batsakis \[[@b4-jptm-2017-11-01]\], defining it as the invasion of tumor cells in, around, and through nerves. Other authors define PNI according to the location of the neoplastic cells with regards to the layers of the nerve sheath (outer epineurium, perineurium, and inner endoneurium). Liebig *et al*. \[[@b5-jptm-2017-11-01]\] defined PNI as the presence of neoplastic cells in any three layers of the nerve sheath or in foci outside the nerve sheath with the involvement of 33% of the nerve circumference. The criterion of PNI defined as cancer cells inside the perineurium and surrounding at least 33% of the nerve circumference showed a perfect interobserver concordance.

PNI was once thought to be an extension of lymphatic metastasis, but recent studies have shown that lymphatic channels do not penetrate the layers of the nerve sheath \[[@b6-jptm-2017-11-01]-[@b8-jptm-2017-11-01]\]. Studies on prostate and pancreatic cancer showed that in PNI there is an interaction of reciprocal neurotrophic factors between the neoplastic cells and the nerves, like nerve growth factor (NGF), brain-derived neurotrophic factor, neurotrophin 3, and neurotrophin \[[@b9-jptm-2017-11-01],[@b10-jptm-2017-11-01]\]. Okada *et al*. \[[@b11-jptm-2017-11-01]\] reported that exogenous NGF leads to a dose-dependent increase in matrix metalloproteinase 2 expression and invasion in neoplastic cells of the pancreas.

In a systematic review and meta-analysis of 30,590 cases on PNI in gastric cancer, Deng *et al*. \[[@b12-jptm-2017-11-01]\] found PNI as an independent predictor of recurrence, as well as to affecting disease-free survival and overall survival in patients with gastric cancer undergoing curative resection. Although most authors focus their attention on evaluating mural perineural invasion (mPNI, invasion of the nerve plexus in the proper muscle and submucosal muscle), there are studies in gastrointestinal cancers (especially colon cancer) that demonstrate that the PNI outside the muscular wall (extramural PNI \[ePNI\]) has a worse prognosis \[[@b13-jptm-2017-11-01]\]. To date, there are no studies subclassifying PNI into mPNI and ePNI in gastric carcinoma.

Our goal was to confirm whether the prognosis associated with PNI is determined by ePNI rather than mPNI under the hypothesis that the patients with ePNI will show worse disease-specific survival (DSS) than those with mPNI, in pT3--pT4 carcinomas in clinical stages II and III.

MATERIALS AND METHODS
=====================

From the database of patients with gastric adenocarcinomas from 2005 to 2015 at the national referral cancer center in Mexico, we searched for patients who underwent curative resection of gastric adenocarcinoma in clinical stages II and III, with pathological tumor stages pT3 and pT4 and with PNI described in the pathological report. Most patients at our institution were at stage IV disease at presentation or in poor clinical conditions and they did not receive surgery. In our center, the same surgical team performs around 30 gastric surgeries per year. Gastrectomy with D2 lymphadenectomy was the standard surgical procedure in all cases. The standard adjuvant therapy was capecitabine/oxaliplatin in selected patients (especially in those who had pathological risk factors and/or low lymph node counts). Data on patient demographics, tumor localization, operation, and histopathological study were recorded. The staging was determined by clinical, radiological, and histopathological data according to the American Joint Commission on Cancer pTNM system (7th edition, 2010) \[[@b14-jptm-2017-11-01]\].

For the selected cases (n = 73), two pathologists with expertise in gastrointestinal pathology separately evaluated a median of five hematoxylin and eosin stained slides (range, 3 to 8) for evaluation of PNI and other pathologic features. Each pathologist was blind to the patient data and the diagnosis of the other pathologist. The criterion of PNI was cancer cells inside the perineuroum involving at least 33% of the nerve circumference ([Fig. 1](#f1-jptm-2017-11-01){ref-type="fig"}) \[[@b5-jptm-2017-11-01],[@b15-jptm-2017-11-01]\]. When PNI was present in the submucosa or *muscularis propria*, the pathologist classified the case as mPNI. If the the tumor invaded a nerve located beyond the *muscularis propria* (subserosal tissue or adventitia), it was classified as ePNI. When the muscular layer could not be identified due to tumor destruction, an imaginary line was drawn between the breakpoints of intact *muscularis propria*. Discordant cases were reviewed by both pathologists under the same microscope for consensus. The tumor was classified as intestinal adenocarcinoma when glandular differentiation was clearly demonstrated and as diffuse adenocarcinoma when there was no glandular differentiation and the tumor was composed of individual cells with or without signet ring cells.

Statistic analysis
------------------

Data were analyzed using the Statistical Package for Social Sciences ver.12.0 (SPSS Inc., Chicago, IL, USA). Kappa statistic for interobserver concordance regarding PNI was performed before consensus between the pathologists. A comparison of the means was performed with an unpaired Student t test. Chi-square and Fisher exact tests were performed to examine associations between categorical variables. In all cases, p-values were two-sided, and a statistical significance was accepted when p \< .05.

Survival analysis
-----------------

The primary end-point was DSS defined as cancer death, determined from the date of the first treatment, including palliative care (event) or last follow-up (censored). The DSS curves were estimated using the Kaplan-Meier method. The univariate Cox regression model was used to examine the association of variables with DSS. Significant characteristics in the univariate analysis (variables with a p \< .05) were introduced into a multivariate model of Cox proportional hazards in addition to age and sex.

This study was approved by the Institutional Review Board and Ethics Committe of the National Cancer Institute of Mexico with a waiver of informed consent because of the retrospective nature of the study (IRB No. CEI.16/117).

RESULTS
=======

Clinicopathologic characteristics
---------------------------------

Features of the patient cohort (n = 73) are summarized in [Table 1](#t1-jptm-2017-11-01){ref-type="table"}. The median age was 56 years old, ranging from 46 to 65 years. Thirty-eight patients (52%) were male and 35 (48%) were female. In total, 68 patients (93%) received total gastrectomy and five received subtotal gastrectomy. Surgery was performed by laparoscopy in 15 cases (20.5%). During the laparotomy or laparoscopy, 22 patients (30.1%) presented with resectable peritoneal, hepatic or splenic metastasis, and all of them were fully resected. Major complications occurred in nine patients (12.3%; i.e., anastomotic leakage, septicemia, dehiscence). PNI was verified in all cases, with a majority (65.7%) in the ePNI group, and the kappa statistic was 1.0 for concordance between observers. There was no difference in clinicopathologic features between the groups including pT and pN stage ([Table 1](#t1-jptm-2017-11-01){ref-type="table"}). Patients with ePNI were less likely to be free of disease (10.4% vs 36%). The percentage of each histologic type of the tumor was also similar between the groups.

Outcome
-------

The median follow-up time was 12 ± 24.6 months, ranging from 5 to 116 months. In this timeframe, 43 patients had recurrence (48.9%): 33 distant and 10 local. The median time to recurrence was 5 months, with a range from 3 to 20 months. The incidence of recurrence was similar between the groups. Of the patient cohort, 19.2% of all patients were alive and free of disease, 27.4% died from the disease, 43.8% were alive with disease, and 9.6% died from causes not related to gastric carcinoma. Patients with ePNI had a higher mortality rate than patients with mPNI (29.2% vs 24%) (p = .023).

Survival analysis
-----------------

The 5-year DSS was 60%. Univariate analysis is summarized in [Table 2](#t2-jptm-2017-11-01){ref-type="table"}. Lymph node metastasis, tumor stage pT4b, presence of ePNI and recurrence were predictors of increased mortality. Patients with PNI showed differences in survival between the groups, with 5-year DSS of 64% for 25 patients with mPNI compared with 50% for 48 patients in the ePNI group (p = .039) ([Fig. 2](#f2-jptm-2017-11-01){ref-type="fig"}). Among the patients in the ePNI group, 14 were dead of disease with a median of 16 months, and 22 patients were alive with disease (recurrence). The median DSS of the patients in the ePNI group was 16 months and for the patients in the mPNI group was 46 months. Most patients (74%) received adjuvant therapy with heterogeneous modalities for subanalysis. All patients with nodal metastasis, lymphovascular invasion and R1 resections received adjuvant therapy. R1 resections had a higher 5-year survival than R0 resections, which can be explained by the rate of adjuvant therapy in the R1 group; however, the difference was not statistically significant.

The only independent adverse prognostic factor identified in multivariate analysis was lymph node metastasis (hazard ratio, 1.757; 95% confidence interval, 1.082 to 2.854; p = .023). The remaining factors including ePNI were not associated with poor DSS as independent factors ([Table 3](#t3-jptm-2017-11-01){ref-type="table"}).

DISCUSSION
==========

PNI has been identified in gastric cancer with a median of 40.9% (6.8%--75.6%) \[[@b12-jptm-2017-11-01]\]. This is the first study subclassifying PNI into mPNi and ePNI in gastric cancer. We found ePNI to be present in equal sex distribution, with a median age of 58 years, more frequent in pT4a tumors, in patients with lymphovascular invasion and associated with a lower DSS compared with mPNI.

In gastric cancer, the prognostic significance of PNI is clear. Tanaka *et al*. \[[@b16-jptm-2017-11-01]\] reported that PNI is a determinant in the prognosis of advanced cancer and found that 80% of patients with peritoneal recurrence had PNI whereas Duraker *et al*. \[[@b17-jptm-2017-11-01]\] showed that PNI was present in 59.9% of patients with disease progression. Bilici *et al*. \[[@b18-jptm-2017-11-01]\] found that the mean survival of patients with PNI was shorter than patients without PNI (60.3 months vs 27.9 months, respectively). Tianhang *et al*. \[[@b19-jptm-2017-11-01]\] found a significant relationship between clinical stage and PNI; both were independent prognostic factors. Finally, Selcukbiricik *et al*. \[[@b20-jptm-2017-11-01]\] and Jiang *et al*. \[[@b21-jptm-2017-11-01]\] demosntrated that PNI is an independent prognostic factor associated with tumor size (\> 5 cm), lymphovascular invasion, pT4 tumors, lymph node metastasis, and advanced stage \[[@b21-jptm-2017-11-01]\].

However, we think that this observations are due to ePNI rather than mPNI based on findings like those by Ueno *et al*. \[[@b13-jptm-2017-11-01]\], who analyzed 364 patients with rectal cancer, dividing PNI into PNI-0 (absence of IPN), PN-1 (less than five PNI foci in the first 10 mm measured from the outer muscle layer), PN-2 (five or more foci or 10 mm or more from the muscularis propria), and reported a 5-year survival of 74%, 50%, and 22%, respectively. They showed that the degrees of PNI were independently associated with local recurrence and long-term survival regardless of tumor depth and lymph node metastasis \[[@b13-jptm-2017-11-01]\]. We applied a similar approach to gastric cancer, demonstrating similar results; an independent worse DSS of patients with ePNI compared with those with mPNI.

The perineural space is a potential route for tumor spread in gastric adenocarcinoma, especially outside muscularis propria in patients with pT3 and pT4 tumors. While in multivariate analysis their association could not be demonstrated as an independent factor for survival, it is clear that it is associated with lower median survival and 5-year DSS. We believe that this difference does not have significance in multivariate analysis in part because of the poor prognosis of these patients due to the advanced pathological stage and possibly inaccurate lymph node stage (some cases in our series had less than 25 lymph nodes in "D2" gastrectomy). However, in order to decrease these potential biases, we only used cases in pT3 and pT4 stages because these are the tumors that invade beyond muscularis propria.

It is plausible that ePNI could be considered in the staging and prognostic systems in gastric cancer to stratify patients with a high risk of recurrence. Our results need to be confirmed in a larger series; however, this study provide us with information on the possibility that PNI behaves differently depending on how it is evaluated, which can explain the lack of consensus on the true prognostic value of PNI.
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![Histologic microphotography showing perineural space invasion. Note that neoplastic glands invade perineurium and encases at least 33% of the circumference of the nerve.](jptm-2017-11-01f1){#f1-jptm-2017-11-01}

![Five-year disease-specific survival of 73 patients with gastric carcinoma divided by perineural invasion.](jptm-2017-11-01f2){#f2-jptm-2017-11-01}

###### 

Clinicopathologic data comparison between 73 gastric carcinomas in pT3 and pT4 stage according perineural invasion

  Variable                                                Intramural (n = 25)   Extramural (n = 48)   p-value^[a](#tfn1-jptm-2017-11-01){ref-type="table-fn"}^
  ------------------------------------------------------- --------------------- --------------------- ----------------------------------------------------------
  Median age (Q1--Q3 range)                               56 (46--65)           58 (47--65)           .783
  Sex                                                                                                 
   Female                                                 12 (48)               23 (47.9)             .617
   Male                                                   13 (52)               25 (52.1)             
  pT                                                                                                  
   pT3                                                    15 (60)               21 (43.8)             .247
   pT4a                                                   10 (40)               24 (50)               
   pT4b                                                   0                     3 (6.3)               
  Nodal metastasis                                                                                    
   N0                                                     5 (20)                8 (16.7)              .423
   N1                                                     12 (48)               25 (52.1)             
   N2                                                     8 (32)                14 (29.2)             
   N3                                                     0                     1 (2.1)               
  Location                                                                                            
   Proximal third                                         5 (20)                11 (22.9)             .759
   Medim third                                            7 (28)                12 (25)               
   Distal third                                           13 (52)               25 (52.1)             
  Median number of dissected lymph nodes (Q1--Q3 range)   26 (19--36)           26 (19--39)           .818
  Median number of positive lymph nodes (Q1--Q3 range)    7 (2--11)             10 (3--22)            .933
  Distant metastases                                                                                  
   No                                                     18 (72)               33 (68.8)             .774
   Yes                                                    7 (28)                15 (31.2)             
  Lymphovascular invasion                                                                             
   No                                                     4 (16)                7 (14.6)              .872
   Yes                                                    21 (84)               41 (85.4)             
  Grade                                                                                               
   Well differentiated                                    2 (8)                 4 (8.3)               .405
   Moderately differentiated                              19 (76)               41 (85.4)             
   Poorly differentiated                                  4 (16)                3 (6.3)               
  Clinical stage                                                                                      
   Stage II                                               7 (28)                10 (20.8)             .770
   Stage III                                              11(44)                22 (45.8)             
   Stage IV                                               7 (28)                16 (33.4)             
  Resection                                                                                           
   R0                                                     24 (96)               44 (91.7)             .487
   R1                                                     1 (4)                 4 (8.3)               
  Adjuvant treatment                                                                                  
   No                                                     3 (12)                16 (33.3)             .137
   Yes                                                    22 (88)               32 (66.7)             
  Overall recurrence                                                                                  
   No                                                     12 (48)               18 (37.5)             .231
   Yes                                                    13 (52)               30 (62.5)             
  Outcome                                                                                             
   Alive free of disease                                  9 (36)                5 (10.4)              .023
   Dead with disease                                      6 (24)                14 (29.2)             
   Alive with disease                                     10 (40)               22 (45.8)             
   Dead without disease                                   0                     7 (14.6)              
  Median follow-up (Q1--Q3 range, mo)                     13 (8--51)            11 (5--19)            .052
  5-Year disease-specific survival (%)                    64                    50                    .039

Values are presented as median (range) or number (%).

Chi square test or Kruskal-Wallis test.

###### 

Univariate analysis of 73 gastric carcinomas^[a](#tfn2-jptm-2017-11-01){ref-type="table-fn"}^

  Variable                      5-Year disease-specific survival (%)   p-value
  ----------------------------- -------------------------------------- ---------
  Sex                                                                  
   Male                         49                                     .591
   Female                       65                                     
  Pathologic tumoral category                                          
   pT3                          67                                     .023
   pT4a                         43                                     
   pT4b                         0                                      
  Clinical stage                                                       
   II                           85                                     
   III                          36                                     .116
   IV                           27                                     
  Lymph node metastasis                                                
   No                           90                                     .001
   Yes                          42                                     
  Distant metastases                                                   
   No                           56                                     .880
   Yes                          46                                     
  Lymphovascular invasion                                              
   No                           90                                     .290
   Yes                          50                                     
  Perineural invasion                                                  
   Intramural                   64                                     .039
   Extramural                   49                                     
  Grade                                                                
   Well differentiated          50                                     .619
   Moderately differentiated    56                                     
   Poorly differentiated        50                                     
  Adjuvant therapy                                                     
   No                           62                                     .713
   Yes                          66                                     
  Resection                                                            
   R0                           52                                     .783
   R1                           60                                     
  Recurrence                                                           
   No                           87                                     .007
   Yes                          42                                     

Mantel-Cox test.

###### 

Multivariate analysis of 73 gastric carcinomas

  Variable                                      Cox hazard ratio   95% CI         p-value
  --------------------------------------------- ------------------ -------------- ---------
  Lymph node metastasis (yes vs no)             1.757              1.082--2.854   .023
  Recurrence (yes vs no)                        1.594              0949--2.676    .078
  Pathologic T category (pT3 vs pT4).           1.187              0.453--3.110   .727
  Extramural perineural invasion (yes vs no).   1.096              0.393--3.054   .861

CI, confidence interval.
